Figure 1:

Schematic overview showing current antibody-based therapeutics for the cancer treatment. There are four major categories of antibody therapeutics. First, monoclonal antibody (mAb), which includes anti-tumor associated antigen (TAA) and T-cell costimulatory/coinhibitory molecules. Second, antibody-drug conjugate. Third, bispecific antibodies. Fourth, immunocytokines. IL-10, interleukin-10; IL-12, interleukin-12; IL-15, interleukin-15; IL-21, interleukin-21; EpCAM, epithelial cell adhesion molecule; BCMA, B-cell maturation antigen; EGFR, epidermal growth factor receptor; HER2, epidermal growth factor receptor 2; PD-L1, programmed cell death 1 ligand 1.